A patient with hyperlipidemia who had a gallbladder stone caused by administration of fenofibrate

Kurume Medical Journal

Volumn 50, Issue 1-2, 2003, Pages 77-80

  Inuzuka, Sadataka ^a   Tomiyasu, Nobuo ^b   Kumamoto, Masafumi ^b   Egashira, Tatunari ^a   Kinoshita, Junnji ^a   Shishido, Syoichiro ^b   Sata, Michio ^b   Ueno, Takato ^c  

^a Inuzuka Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

Fenofibrate; Gallbladder stone; Hyperlipidemia; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

CLOFIBRATE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ARTICLE; BLOOD CHEMISTRY; CASE REPORT; CHOLELITHIASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERLIPIDEMIA;

EID: 0042473219     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.50.77     Document Type: Article

References (15)

1. Report from the committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40:1069-1118.
2. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994; 111:161-174.
3. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-510.
4. Schoonjans K, Staels B, and Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Lipid Res 1996; 37:907-925.
5. Caroli-Bosc FX, Le Gall P, Pugliese P, Delabre B, Caroli-Bosc C et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001; 46:540-544.
6. Sxhonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M et al. PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via PPRE in the lipoprotein lipase gene. EMBO 1996; 15:5336-5348.
7. Staels B, Dallongeville J, Schoonjans K, Leitersdorf E, and Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093.
8. Jen S-L, Chen JW, Lee WL, and Wang S-P. Efficacy and safety of fenofibrate or gemifibrozil on serum lipid profiles in Chinese patients with type Iib hyperlipidemia: a single-blind, randomiged, and cross-over study. Chung Hua I Hsueh Tsa Chih (Taipei) 1997; 59:217-224.
9. Brown WV, Dujovne CA, Farquhar WJ, Feldman EB, Grundy SM et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type IIA or Iib hyperlipidemia. Arteriosclerosis 1986;6:670-678.
10. Knopp RH, Walden CE, Warnick GR, Alvers JJ, Ginsberg J et al. Effects of fenofibrate treatment on plasma lipoprotein lipid, high density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Am J Med 1998; 83:75-84.
11. Grundy SM, Ahrens EHJr, Salen G, Schreibman PH, and Nestel PJ. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 1972; 13:531-551.
12. The Coronary Drug project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism: experience in the Coronary Drug Project. N Engl Med 1997; 296:1185-1190.
13. Kimberly DS, Joe AC, Mohammad ZA, Sheila R, Sarkis FF et al. Lovastin inhibits Gallstone formation in the cholesterol-fed prairie dog. Ann Surg 1991; 214:149-154.
14. Tazuma S, Hatsushika S, Aihara N, Sagawa H, Yamasita G et al. Inhibitory effects of pravastatin, a comperitive inhibitor of hydroxymethylglutaryl coenzyme a recluctase, on cholesterol gallstone formation in prairie dogs. Digestion 1992; 51:179-184.
15. Bateson MC. Simbastatin and ursodeoxycholic acid for rapid gallstone dissolution. Lancet 1990; 336(8724):1196.